Molnupiravir for the Treatment of COVID-19. Information for Health Professionals
Data
2022Número do documento
PAHO/HSS/MT/COVID-19/22-0021
Metadata
Mostrar registro completoOutros idiomas
Resumo
The Pan American Health Organization presents this information sheet with recommendations on the use of molnupiravir addressed to health professionals. Molnupiravir is a prodrug that significantly inhibits SARS-CoV-2 replication. It is used for the treatment of mild and moderate COVID-19 in patients who are at high risk of complications, and has shown a significant reduction in the rate of hospitalization or death of patients with COVID-19.
Collections
Este aviso deve ser preservado juntamente com o URL original do artigo.Attribution-NonCommercial-ShareAlike 3.0 IGO
Itens relacionados
Apresentado os itens relacionados pelo título, autor e assunto.
-
Pan American Health Organization; Health Systems and Services (HSS) (PAHOUnited StatesWashington, D.C., 2022)The Pan American Health Organization presents this information sheet with recommendations on the use of molnupiravir addressed to patients. Molnupiravir is a prodrug that significantly inhibits SARS-CoV-2 replication. It ...
-
Pan American Health Organization; Evidence and Intelligence for Action in Health (EIH) (PAHOUnited StatesWashington, D.C., 2022)Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression ...
-
Organización Panamericana de la Salud; Health Systems and Services (HSS) (OPSUnited StatesWashington, D.C., 2022)La Organización Panamericana de la Salud presenta esta ficha informativa con recomendaciones sobre el uso del molnupiravir dirigidas a los profesionales de la salud. El molnupiravir es un profármaco que inhibe de manera ...